Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/26234
Title: | Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes | Authors: | Gargiulo, Giuseppe Carrara, Greta Frigoli, Enrico VRANCKX, Pascal Leonardi, Sergio Ciociano, Nestor Campo, Gianluca Varbella, Ferdinando Calabro, Paolo Garducci, Stefano Iannone, Alessandro Briguori, Carlo Ando, Giuseppe Crimi, Gabriele Limbruno, Ugo Garbo, Roberto Sganzerla, Paolo Russo, Filippo Lupi, Alessandro Cortese, Bernardo Ausiello, Arturo Ierna, Salvatore Esposito, Giovanni Zavalloni, Dennis Santarelli, Andrea Sardella, Gennaro Tresoldi, Simone de Cesare, Nicoletta Sciahbasi, Alessandro Zingarelli, Antonio Tosi, Paolo van't Hof, Arnoud Omerovic, Elmir Brugaletta, Salvatore Windecker, Stephan Valgimigli, Marco |
Issue Date: | 2018 | Source: | JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 71(11), p. 1231-1242 | Abstract: | BACKGROUND Contrasting evidence exists on the comparative efficacy and safety of bivalirudin and unfractionated heparin (UFH) in relation to the planned use of glycoprotein IIb/IIIa inhibitors (GPIs). OBJECTIVES This study assessed the efficacy and safety of bivalirudin compared with UFH with or without GPIs in patients with acute coronary syndrome (ACS) who underwent invasive management. METHODS In the MATRIX (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX) program, 7,213 patients were randomly assigned to receive either bivalirudin or UFH with or without GPIs at discretion of the operator. The 30-day coprimary outcomes were major adverse cardiovascular events (MACEs) (a composite of death, myocardial infarction, or stroke), and net adverse clinical events (NACEs) (a composite of MACEs or major bleeding). RESULTS Among 3,603 patients assigned to receive UFH, 781 (21.7%) underwent planned treatment with GPI before coronary intervention. Bailout use of GPIs was similar between the bivalirudin and UFH groups (4.5% and 5.4%) (p = 0.11). At 30 days, the 2 coprimary endpoints of MACEs and NACEs, as well as individual endpoints of mortality, myocardial infarction, stent thrombosis or stroke did not differ among the 3 groups after adjustment. Compared with the UFH and UFH+GPI groups, bivalirudin reduced bleeding, mainly the most severe bleeds, including fatal and nonaccess site-related events, as well as transfusion rates and the need for surgical access site repair. These findings were not influenced by the administered intraprocedural dose of UFH and were confirmed at multiple sensitivity analyses, including the randomly allocated access site. CONCLUSIONS In patients with ACS, the rates of MACEs and NACEs were not significantly lower with bivalirudin than with UFH, irrespective of planned GPI use. However, bivalirudin significantly reduced bleeding complications, mainly those not related to access site, irrespective of planned use of GPIs. (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX [MATRIX]; NCT01433627) (c) 2018 by the American College of Cardiology Foundation. | Notes: | Valgimigli, M (reprint author), Bern Univ Hosp, Dept Cardiol, Freiburgstr 4, CH-3010 Bern, Switzerland, marco.valgimigli@insel.ch | Keywords: | acute coronary syndrome; bivalirudin; GP IIb/IIIa inhibitor; heparin; MATRIX | Document URI: | http://hdl.handle.net/1942/26234 | ISSN: | 0735-1097 | e-ISSN: | 1558-3597 | DOI: | 10.1016/j.jacc.2018.01.033 | ISI #: | 000427463400007 | Rights: | (C) 2018 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2019 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
gargiulo2018.pdf Restricted Access | Published version | 451.68 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
18
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
33
checked on Jul 27, 2024
Page view(s)
78
checked on Jul 20, 2022
Download(s)
54
checked on Jul 20, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.